A new study has found that weight-reducing GLP-1 drugs can help obese people manage knee arthritis pain.
Research results show that people who received weekly injections of semaglutide, the active agent in the diabetes drug Ozempic and the weight-loss drug Wegovy, lost about 14 percent of their body weight after 68 weeks.
In addition, in comparison, 3 percent of people were given a placebo. The trial was funded by Novo Nordisk, which makes the semaglutide drug.
This weight loss resulted in decreased knee pain and improved knee function in those taking semaglutide. The researchers have published a report in the New England Journal of Medicine.
“Obesity-related osteoarthritis of the knee is a progressive condition that can cause knee pain and stiffness and make it difficult to perform important daily tasks such as walking or walking,” said Dr. Henning Blaedel, professor of rheumatology at Copenhagen University Hospital. I can be a hindrance.
